Crucial factors guiding therapy decisions include tumor size, grading, the proliferation marker Ki67, patient age, genetic risk factors, results of gene expression tests, and any prior medical conditions that could impact treatment choices [2]. This evidence concerns the gene MKI67 and neoplasm.